dc.contributor.author | Holland, DJ | |
dc.contributor.author | Marwick, TH | |
dc.contributor.author | Haluska, BA | |
dc.contributor.author | Leano, R | |
dc.contributor.author | Hordern, MD | |
dc.contributor.author | Hare, JL | |
dc.contributor.author | Fang, ZY | |
dc.contributor.author | Prins, JB | |
dc.contributor.author | Stanton, T | |
dc.date.accessioned | 2022-01-25T09:57:12Z | |
dc.date.available | 2022-01-25T09:57:12Z | |
dc.date.issued | 2015 | |
dc.identifier.issn | 1355-6037 | |
dc.identifier.doi | 10.1136/heartjnl-2014-307391 | |
dc.identifier.uri | http://hdl.handle.net/10072/411736 | |
dc.description.abstract | Objective: New imaging techniques have permitted the detection of subclinical LV dysfunction (LVD) in up to half of patients with type 2 diabetes mellitus (DM) with a normal EF. However, the connection between early LVD and prognosis is unclear. This study aimed to define the long-term outcome of LVD associated with type 2 DM. Methods: In this prospective cohort study, 230 asymptomatic patients with type 2 DM underwent measurement of global longitudinal 2D strain (GLS) for detection of LVD and were followed for up to 10 years. All subjects had normal EF (≥50%) and no evidence of coronary artery disease at recruitment. Outcome data were obtained through centralised state-wide death and hospital admission registries. The primary endpoint was all-cause mortality and hospitalisation. Results: On study entry, almost half (45%) of the cohort had evidence of LVD as detected by GLS. Over a median follow-up of 7.4±2.6 years (range 0.6-9.7 years), 68 patients (30%) met the primary endpoint (LVD: 37%; normal LV function: 24%). GLS was independently associated with the primary endpoint (HR=1.10; p=0.04), as was systolic blood pressure (HR=1.02; p<0.001) and levels of glycosylated haemoglobin (HR=1.28; p=0.011). Patients with LVD had significantly worse outcome than those without (χ2=4.73; p=0.030). Conclusions: Subclinical LVD is common in asymptomatic patients with type 2 DM, is readily detectable by GLS imaging and is independently associated with adverse outcome. Trial registration number: Australian and New Zealand Clinical Trials Registry (ACTRN12612001178831). | |
dc.description.peerreviewed | Yes | |
dc.language | eng | |
dc.publisher | BMJ | |
dc.relation.ispartofpagefrom | 1061 | |
dc.relation.ispartofpageto | 1066 | |
dc.relation.ispartofissue | 13 | |
dc.relation.ispartofjournal | Heart | |
dc.relation.ispartofvolume | 101 | |
dc.subject.fieldofresearch | Cardiovascular medicine and haematology | |
dc.subject.fieldofresearch | Clinical sciences | |
dc.subject.fieldofresearchcode | 3201 | |
dc.subject.fieldofresearchcode | 3202 | |
dc.title | Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dcterms.bibliographicCitation | Holland, DJ; Marwick, TH; Haluska, BA; Leano, R; Hordern, MD; Hare, JL; Fang, ZY; Prins, JB; Stanton, T, Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus, Heart, 2015, 101 (13), pp. 1061-1066 | |
dcterms.dateAccepted | 2015-04-13 | |
dc.date.updated | 2022-01-25T09:56:19Z | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Stanton, Tony | |
gro.griffith.author | Holland, David J. | |